Clinical Trial

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Protocol Amendment History 3 changes
notable Trial sites expanded: 58 -> 61 locations 2026-08-06
notable Trial sites reduced: 61 -> 58 locations 2026-07-02
notable Trial sites expanded: 45 -> 61 locations 2026-04-14
Trial Details
NCT Number NCT06872125
Lead Sponsor Stoke Therapeutics, Inc
Conditions Dravet Syndrome
Enrollment 170 participants
Start Date 2025-06-04
Primary Completion 2027-03 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-05